Enjoy complimentary customisation on priority with our Enterprise License!
The plasma therapeutics market size is estimated to grow by USD 6.37 million at a CAGR of 4.5% between 2023 and 2028. Albumin, an essential protein used in various medical applications, is experiencing high demand in China due to its role in trauma care, wound healing, and intravenous fluid therapy. The Chinese market witnesses a surge in demand as the number of surgical procedures increases, driven by an aging population and rising healthcare expenditures. Furthermore, recent approvals by governing bodies such as the National Medical Products Administration (NMPA) for new indications and formulations of albumin further fuel market growth. These factors position China as a significant market for albumin, offering lucrative opportunities for manufacturers and suppliers.
For More Highlights About this Report, Request Free Sample
Plasma therapeutics refer to the use of plasma, the liquid component of blood, as a source of therapeutic agents. Plasma contains various essential proteins such as platelets, white blood cells, and red blood cells, as well as plasma protein therapies like enzymes, salts, antibodies, and immunoglobulins. These therapies are used to treat various chronic diseases, life-threatening conditions, and rare genetic disorders. Plasma protein therapies play a crucial role in addressing coagulation factor deficiencies, hemostasis, and autoimmune disorders. For instance, fibrinogen, a coagulation factor, is used to treat hemorrhagic diathesis, while albumin and immunoglobulin are used to manage conditions like coronary heart disease, neuropathic pain, and cancer. Plasma therapeutics have gained significant importance in medicine due to their ability to provide effective therapeutic options for treating chronic diseases, life-threatening conditions, and rare genetic disorders. Plasma protein therapies are also used to manage aging-related conditions and various autoimmune disorders. The market for plasma therapeutics is expected to grow significantly due to the increasing prevalence of chronic diseases, an aging population, and advancements in plasma protein therapy technologies. Some of the key plasma protein therapies include fibrinogen, albumin, immunoglobulin, and various clotting factors used to treat coagulation factor deficiencies. Other plasma protein therapies include enzymes, salts, and antibodies used to treat various conditions like dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia, and genetic disorders. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high demand for albumin in China is notably driving market growth. The market encompasses various applications, including the treatment of pediatric HIV, trauma, inherited bleeding disorders such as Hemophilia A and Hemophilia B, autoimmune disorders, cancer, and coagulation factor deficiencies. Biologics, specifically the Immunoglobulin segment, dominate this market due to their effectiveness in addressing various therapeutic needs. Novel therapeutics, such as source plasma, are gaining popularity as they offer potential advantages over traditional treatments. The demand for plasma products, particularly albumin and immunoglobulins, is increasing due to their applications in volume replacement therapy, kidney diseases, cirrhosis, and cancer. However, the supply of these products is being challenged by stringent regulations on raw material sourcing and import bans. For instance, China, one of the largest markets for albumin, has prohibited the import of plasma and blood-derived products since 1986, except for human albumin. Additionally, plasma therapeutics are used for conditions like neuropathic pain, myasthenia gravis, post-polio syndrome, liver disease, malaria, sepsis, Alzheimer's disease, and hepatitis B. Subcutaneous Immunoglobulin and IgM antibody agonists are product segments gaining traction in oncology and immunology. Clotting factor VIII and Alpha 1 antitrypsin are essential components in addressing hemorrhagic diatheses, including dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Fibrinogen, a crucial clotting factor, is another essential plasma component used in hemostasis. In summary, the Plasma Therapeutics Market is a significant and diverse industry, addressing various medical conditions through biologics, particularly albumin and immunoglobulins. The market is influenced by regulatory challenges, raw material sourcing, and the increasing demand for novel therapeutics. China, as a major market for albumin, presents unique challenges due to import restrictions. Other applications, such as oncology, immunology, and liver diseases, are also driving the growth of this market. Thus, such factors are driving the growth of the market during the forecast period.
The establishment of plasma fractionation facilities in developing economies by global players is the key trend in the market. Plasma therapeutics, a segment of the biologics market, encompasses the use of plasma-derived proteins for treating various medical conditions. The Immunoglobulin segment, which includes Immunoglobulin G (IgG) for Pediatric HIV and other immunodeficiency disorders, holds a significant market share. Additionally, the Haemophilia segment, which caters to inherited bleeding disorders like Hemophilia A and Hemophilia B, is a substantial contributor. Novel therapeutics, such as IgM antibody agonists, are gaining traction in oncology and immunology. Plasma fractionation, essential for the production of these therapeutics, is witnessing a shift towards developing economies due to cost advantages. These countries, including the Middle East, Africa, China, and India, offer easy access to skilled personnel, raw materials, and cheap labor. Moreover, supportive government regulations and a large population base ensure a steady supply of plasma. For instance, Oryx Biotech Holdings, a China-based company, recently initiated the construction of a plasma fractionation plant in Bangladesh.
Plasma therapeutics find applications in diverse medical conditions, such as coagulation factor deficiency, autoimmune disorders, and cancer. Fibrinogen, a crucial clotting factor, is used to manage hemorrhagic diathesis, including dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Albumin, another plasma protein, is used for treating neuropathic pain, myasthenia gravis, post-polio syndrome, liver disease, malaria, sepsis, and Alzheimer's disease. Subcutaneous Immunoglobulin is a product segmentation for Immunoglobulin, which is gaining popularity due to its convenience. Plasma fractionation is also used in the treatment of conditions like coronary heart disease, hemostasis, and clotting factor VIII deficiency. Furthermore, plasma proteins like Alpha 1 antitrypsin are used to manage liver cirrhosis and hepatitis B. In summary, plasma therapeutics, derived from source plasma, offer a wide range of therapeutic options for various medical conditions, and the global market is expected to grow significantly due to the increasing demand for these life-saving treatments. Thus, such trends will shape the growth of the market during the forecast period.
The existence of plasma fractionation supply and demand gap is the major challenge that affects the growth of the market. The Plasma Therapeutics Market encompasses a range of blood-derived products used to address various medical conditions, including pediatric HIV, trauma, inherited bleeding disorders such as Hemophilia A and B, autoimmune disorders, cancer, and coagulation factor deficiencies. These therapeutics are derived from source plasma and include immunoglobulins, clotting factors, and albumin. The Immunoglobulin segment holds a significant market share due to its application in treating conditions like neuropathic pain, myasthenia gravis, post-polio syndrome, liver disease, malaria, sepsis, and Alzheimer's disease.
The Haemophilia segment is another substantial market, driven by the increasing prevalence of hemorrhagic diatheses like dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Novel therapeutics, such as IgM antibody agonists and oncology and immunology applications, are also gaining traction. However, the global plasma supply and fractionation capacity are currently constrained, leading to a significant demand-supply gap. Major players in the market include Baxter, Grifols, and CSL Behring, who are working to address this challenge and expand their product offerings, including subcutaneous Immunoglobulin and product segmentation in areas like hepatitis B and clotting factor VIII. The aging population and the increasing prevalence of coronary heart disease and other chronic conditions further fuel the demand for these therapeutics. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
ADMA Biologics Inc. - The company offers human immunoglobulin that is purified from source human plasma and processed using a modified classical Cohn-Oncley fractionation procedure.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The immunoglobulin segment is estimated to witness significant growth during the forecast period. Plasma therapeutics encompass a range of biologics derived from source plasma, providing therapeutic options for various conditions such as Pediatric HIV, trauma, inherited bleeding disorders like Hemophilia A and Hemophilia B, coagulation factor deficiencies, autoimmune disorders, cancer, and hemostatic disorders including dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia. Immunoglobulin (IG) segment includes subcutaneous IG and intravenous IG, which are essential in treating conditions where corticosteroids are ineffective.
Get a glance at the market share of various regions Download the PDF Sample
The immunoglobulin segment accounted for USD 13.79 million in 2018. Subcutaneous IG is injected under the skin, while intravenous Ig is administered through veins. Intravenous IG is frequently used in autoimmune hemolytic anemia, either alone or in conjunction with prednisone. These drugs have proven effectiveness, particularly in children, with relatively fewer adverse effects compared to other treatment options. The therapeutic value of these drugs, used alone or in combination, will fuel market growth during the forecast period. Additionally, plasma therapeutics have applications in oncology, immunology, liver disease, malaria, sepsis, Alzheimer's disease, and other conditions such as neuropathic pain, myasthenia gravis, post-polio syndrome, and hepatitis B. Clotting factor VIII and alpha 1 antitrypsin are other essential plasma-derived therapeutics.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the market forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Plasma, a vital component of blood, is utilized in various therapeutic applications due to its rich content of water, platelets, white blood cells, red blood cells, plasma protein therapies, enzymes, salts, antibodies, and proteins.
Plasma is increasingly being used to treat chronic diseases, life-threatening conditions, and rare genetic diseases. Plasma protein therapies are effective in managing immune deficiency disorders, autoimmune disorders, neurological disorders, bleeding disorders, shocks, burns, and blood transfusion complications in hospitals. Production and processing methods have significantly advanced, enabling the production of plasma-derived therapies for various indications such as immune deficiency disorders, hereditary autoimmune diseases, and cardiovascular and neurological diseases. Alpha 1 Antitrypsin Deficiency, Von Willebrand Disease, and Antithrombin III Deficiency are some of the common indications. Plasma is also used in organ transplants, liver surgery, and cardiopulmonary disease treatment. Reimbursement policies and risk factors impact the market growth. Cardiovascular diseases and neurological diseases are significant indications driving the market. Plasma is essential in treating severe infections, sepsis, and trauma. Plasma is also used in treating animal bites and hemorrhage. Despite the benefits, challenges such as high production costs, limited supply, and potential contamination risks remain. The geriatric population's increasing prevalence and the rising incidence of immune deficiency disorders, neurological diseases, and hepatitis further fuel the market growth. However, stringent regulatory requirements and the availability of alternative therapies may hinder market expansion.
The market report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Plasma, a vital component of blood, is increasingly being utilized in therapeutic applications due to its rich composition of proteins, enzymes, antibodies, and salts. Plasma protein therapies, derived from donated human plasma, are used to treat various chronic diseases, life-threatening conditions, and rare genetic disorders. These therapies find application in managing immune deficiencies, autoimmune disorders, neurological disorders, bleeding disorders, shocks, burns, and other medical emergencies. Production methods and processing techniques play a crucial role in ensuring the safety and efficacy of plasma-derived therapies. Plasma is sourced from voluntary donors and undergoes rigorous testing to ensure the absence of infectious agents. Plasma protein therapies are used to treat conditions like Von Willebrand Disease, Antithrombin III Deficiency, Alpha 1 Antitrypsin Deficiency, and Cardiopulmonary disease, among others. The market is driven by the increasing prevalence of chronic diseases, life-threatening conditions, and rare genetic disorders. The geriatric population, with its higher susceptibility to immune deficiency disorders, is a significant consumer of these therapies. Reimbursement policies and risk factors associated with certain diseases also influence market growth. Cardiovascular diseases and neurological diseases are major indications for plasma protein therapies. Plasma is also used in organ transplants and liver surgery. However, the high cost of production and the risk of contamination pose challenges to the market.
Market Scope |
|
Report Coverage |
Details |
Page number |
147 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market growth 2024-2028 |
USD 6.37 billion |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
4.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, Germany, UK, Canada, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
ADMA Biologics Inc., Bio Products Laboratory Ltd., BIOPHARMA PLASMA, CSL Ltd., Emergent BioSolutions Inc., Evolve Biologics Inc., Grifols SA, Kamada Ltd., Kedrion Spa, Octapharma AG, Pfizer Inc., Prothya Biosolutions Netherlands BV, SK Inc., and Takeda Pharmaceutical Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.